title: Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
abstract: Methylenetetrahydrofolate reductase (MTHFR) enzyme is essential for transmethylation reactions including DNA methylation and DNA synthesis and thereby may contribute to cancer prognosis. In our study, a total of 1,004 advanced non-small cell lung cancer (NSCLC) patients receiving first-line, platinum-based chemotherapy regimens were used for genotyping 10 tag single nucleotide polymorphisms (SNPs) of MTHFR. Association was assessed between the SNPs and treatment outcomes. We found that polymorphism of rs1537514 showed the most significant effect: heterozygote associated with better clinical benefit (P = 0.002) and decreased risk of grade 3 or 4 gastrointestinal toxicity (P = 0.027), while the mutant homozygote associated with increased risk of severe gastrointestinal toxicity (P = 0.031) and thrombocytopenia (P = 009). The heterozygotes of exon polymorphisms (rs1801131, rs1801133) also yielded better clinical benefit (P = 0.030 for rs1801131) and decreased risk of severe gastrointestinal toxicity (P = 0.004 for rs1801131) or thrombocytopenia (P = 0.016 for 1801133). However, overall survival (OS) and progression-free survival (PFS) did not differ for the MTHFR polymorphisms, except for heterozygote of rs1537514 showing significant effects with better PFS (P = 0.022). Clinical factors as age, gender, and smoking status had significant effects for the OS (P = 0.003, 0.002, and 0.012, respectively) while performance status and chemotherapy regimens for PFS (P = 0.001 and 3.9 × 10(-6), respectively). The results indicate that a heterozygous advantage may exist in certain MTHFR variants, and the polymorphisms (especially rs1537514) may play a predictive role of treatment efficacy and adverse effects in NSCLC patients treated with platinum-based chemotherapy.
authors.affiliation: State Key Laboratory of Genetic Engineering, Fudan-VARI Genetic Epidemiology Center and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, 200433, Shanghai, China.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Li
authors.forename: Minhua
authors.initials: M
authors.lastname: Shao
authors.forename: Shiming
authors.initials: S
authors.lastname: Wang
authors.forename: Xueying
authors.initials: X
authors.lastname: Zhao
authors.forename: Hongyan
authors.initials: H
authors.lastname: Chen
authors.forename: Ji
authors.initials: J
authors.lastname: Qian
authors.forename: Xiao
authors.initials: X
authors.lastname: Song
authors.forename: Jiucun
authors.initials: J
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Jin
authors.forename: Junjie
authors.initials: J
authors.lastname: Wu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Chunxue
authors.initials: C
authors.lastname: Bai
authors.forename: Baohui
authors.initials: B
authors.lastname: Han
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Gao
authors.forename: Daru
authors.initials: D
authors.lastname: Lu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D005500:Follow-Up Studies; D006579:Heterozygote; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D014747:Vinblastine; D016190:Carboplatin; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine; D000093542:Gemcitabine
references.citation: PLoS One. 2013 Oct 22;8(10):e78138
references.pmid: 24167601
references.citation: Clin Lung Cancer. 2004 May;5(6):360-5
references.pmid: 15217535
references.citation: Mutat Res. 2001 Apr 18;475(1-2):7-20
references.pmid: 11295149
references.citation: Cell Mol Life Sci. 2012 May;69(10):1705-15
references.pmid: 22193912
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Am J Clin Nutr. 2008 Oct;88(4):1149-58
references.pmid: 18842806
references.citation: Breast Cancer Res. 2007;9(5):R71
references.pmid: 17945002
references.citation: Pharmacogenomics. 2011 Jun;12(6):797-808
references.pmid: 21605004
references.citation: PLoS One. 2012;7(12):e51330
references.pmid: 23227261
references.citation: Lung Cancer. 2005 Sep;49(3):299-309
references.pmid: 15922487
references.citation: PLoS One. 2011;6(8):e23716
references.pmid: 21858212
references.citation: Inflamm Bowel Dis. 2009 Dec;15(12):1784-93
references.pmid: 19685447
references.citation: Ann Thorac Surg. 2006 Mar;81(3):1021-7
references.pmid: 16488713
references.citation: J Clin Oncol. 2009 Apr 20;27(12):2038-45
references.pmid: 19307503
references.citation: Ann Oncol. 2009 Oct;20(10):1660-6
references.pmid: 19465420
references.citation: Clin Cancer Res. 2011 Jun 1;17(11):3822-9
references.pmid: 21471424
references.citation: Biochemistry. 2006 Apr 18;45(15):4808-18
references.pmid: 16605249
references.citation: J Hum Genet. 2011 Jan;56(1):17-21
references.pmid: 20962791
references.citation: Cancer. 2012 Jul 15;118(14):3587-98
references.pmid: 22072145
references.citation: Zhongguo Fei Ai Za Zhi. 2006 Dec 20;9(6):519-24
references.pmid: 21182814
references.citation: Ann Surg. 2001 Jul;234(1):10-20
references.pmid: 11420478
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1089-96
references.pmid: 11588136
references.citation: Dement Geriatr Cogn Disord. 2011;32(3):159-63
references.pmid: 21997345
references.citation: J Nutr. 2003 Nov;133(11 Suppl 1):3731S-3739S
references.pmid: 14608107
references.citation: Chin Med J (Engl). 2004 Nov;117(11):1607-10
references.pmid: 15569473
references.citation: Lancet. 1998 May 23;351(9115):1554-5
references.pmid: 10326541
references.citation: Oncol Lett. 2013 Apr;5(4):1165-1170
references.pmid: 23599757
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3290-5
references.pmid: 9096386
references.citation: J Zhejiang Univ Sci B. 2013 Mar;14(3):207-15
references.pmid: 23463763
references.citation: Lung Cancer. 2013 Sep;81(3):480-486
references.pmid: 23896023
references.citation: Gut. 2014 Apr;63(4):635-46
references.pmid: 23704319
references.citation: Am J Hum Genet. 1998 May;62(5):1044-51
references.pmid: 9545395
references.citation: Future Oncol. 2009 May;5(4):523-42
references.pmid: 19450180
references.citation: Blood. 2010 Jun 10;115(23):4820-3
references.pmid: 20385791
references.citation: Nutr Metab Cardiovasc Dis. 2013 Jul;23(7):693-8
references.pmid: 22647417
references.citation: J Clin Oncol. 2010 Nov 20;28(33):4945-52
references.pmid: 20940192
references.citation: Atherosclerosis. 2001 Jun;156(2):409-15
references.pmid: 11395038
references.citation: Nat Genet. 1995 May;10(1):111-3
references.pmid: 7647779
references.citation: Carcinogenesis. 2011 Dec;32(12):1867-71
references.pmid: 21965272
references.citation: Lung Cancer. 2011 May;72(2):238-43
references.pmid: 20943283
references.citation: Am J Physiol. 1997 Aug;273(2 Pt 1):G258-66
references.pmid: 9277402
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: PLoS One. 2011;6(7):e21851
references.pmid: 21765920
references.citation: Lung Cancer. 2012 Oct;78(1):92-9
references.pmid: 22889494
references.citation: Clin Cancer Res. 2010 Apr 15;16(8):2383-90
references.pmid: 20332326